研究分析化学发光法对人抗丙型肝炎病毒抗体(Human Hepatitis C virus antibodies,Anti-HCV)检测的临床应用价值。方法:随机选取我院2021年1月至2022年12月的30例丙型肝炎患者,将其视为本研究观察对象,对其采取时间分辨荧光免疫法、化...研究分析化学发光法对人抗丙型肝炎病毒抗体(Human Hepatitis C virus antibodies,Anti-HCV)检测的临床应用价值。方法:随机选取我院2021年1月至2022年12月的30例丙型肝炎患者,将其视为本研究观察对象,对其采取时间分辨荧光免疫法、化学发光法对其Anti-HCV进行检查,研究分析其临床应用价值。结果:化学发光法临床Anti-HCV检出率高于时间分辨荧光免疫法,且检测时间低于时间分辨荧光免疫法,具备统计学差异(P<0.05)。结论:在临床检测Anti-HCV中使用化学发光法取得的临床应用价值较高,与时间分辨荧光免疫法相比,化学发光法能够提高临床检测的准确率,缩短检测时间,能够为临床诊疗方案的制定给予良好的参考依据,值得推荐。展开更多
The study included 200 thalassemia patients, 120 （60%） males and 80 （40%） females, at age 2-30 years the mean age 16 years and 100 persons from blood donors at age 20-50 years, the mean age 35 years, as control gr...The study included 200 thalassemia patients, 120 （60%） males and 80 （40%） females, at age 2-30 years the mean age 16 years and 100 persons from blood donors at age 20-50 years, the mean age 35 years, as control group. The authors used ELISA HCV 3.0 to detect anti-HCV in serum of thalassemia patients and blood donors. The results show 17% positive, 76% negative and 7% equivocal in serum ofthalassemia patients, but show 1% positive, 98% negative, 1% equivocal in serum of blood donors. The results show significant difference in P ≤ 0.05 between prevalence of anti-HCV antibodies among thalassemia patients and blood donors, the confirmatory tests by recombinant immunoblot assay version 3.0 （RIBA） show 17.5% positive, 79% negative and 3.5% equivocal in serum of thalassemia patients but show 2% positive, 98% negative in serum of blood donors. The thalassemia patients in the present study region had high seroprevalence of anti-HCV.展开更多
Chronic hepatitis C virus(HCV)infection has become a major public health burden worldwide.Twenty-two sophocarpinic acid or matrine derivatives were synthesized and their anti-HCV activities were evaluated in vitro.The...Chronic hepatitis C virus(HCV)infection has become a major public health burden worldwide.Twenty-two sophocarpinic acid or matrine derivatives were synthesized and their anti-HCV activities were evaluated in vitro.The structure-activity analysis revealed that(i)sophocarpinic acids with a D-seco 3-ring structure scaffold were more favorable than matrines with a 4-ring scaffold;(ii)the introduction of an electron-withdrawing group on the phenyl ring in 12-N-benzenesulfonylΔβγsophocarpinic acids was beneficial for the antiviral activity against HCV.Among them,compounds 9h and 9j exhibited the most potent inhibitory activities on HCV replication with selectivity indies of 70.3 and 30.9,respectively.Therefore,both were selected as antiviral candidates for further investigation.展开更多
A series of novel N-phenylbenzamide and N-phenylacetophenone compounds were synthesized and evaluated for their antiviral activity against HCV and EV71(strain SZ-98).The biological results showed that three compounds(...A series of novel N-phenylbenzamide and N-phenylacetophenone compounds were synthesized and evaluated for their antiviral activity against HCV and EV71(strain SZ-98).The biological results showed that three compounds(23,25 and 41) exhibited considerable anti-HCV activity(IC50? 0.57–7.12 μmol/L) and several compounds(23,28,29,30,31 and 42) displayed potent activity against EV71 with the IC50 values lower than 5.00 μmol/L.The potency of compound 23(IC50? 0.57 μmol/L) was superior to that of reported compounds IMB-1f(IC50? 1.90 μmol/L) and IMB-1g(IC50? 1.00 μmol/L) as anti-HCV agents,and compound29 possessed the highest anti-EV71 activity,comparable to the comparator drug pirodavir.The efficacy in vivo and antiviral mechanism of these compounds warrant further investigations.展开更多
Two hundred and ninety-six samples of patient serum and 28 samples of donor serum were tested for anti-HCV with second generation domestic made testing kit,and for HCV RNA with PCR assay.The purpose of the study was
目的评价人类免疫缺陷病毒(human immunodeficiency virus,HIV)和丙型肝炎病毒(hepatitis C virus,HCV)共感染患者基于含依非韦伦(Efavirenz,EFV)方案抗HIV下直接抗HCV治疗的疗效和安全性。方法选取2020年1月至2023年9月梧州市第三人民...目的评价人类免疫缺陷病毒(human immunodeficiency virus,HIV)和丙型肝炎病毒(hepatitis C virus,HCV)共感染患者基于含依非韦伦(Efavirenz,EFV)方案抗HIV下直接抗HCV治疗的疗效和安全性。方法选取2020年1月至2023年9月梧州市第三人民医院感染科收治的基于含EFV方案抗HIV下索磷布韦维帕他韦直接抗HCV治疗的HIV和HCV共感染患者21例,疗程12周,停药随访12周,分析患者基线特征,比较治疗前后白细胞、血红蛋白、血小板、肝肾功能,评估患者基于抗HIV情况下直接抗HCV治疗的疗效以及停药12周病毒持续应答率和安全性。结果21例HIV和HCV共感染的患者基于含EFV方案抗HIV下,接受索磷布韦维帕他韦抗HCV治疗12周,停药随访12周,HCV病毒应答率均达到100%。与治疗前比较,患者血清丙氨酸转氨酶和天冬氨酸转氨酶水平降低(P<0.01),白细胞、血小板、血肌酐差异无统计学意义(P>0.05)。结论HIV和HCV共感染患者基于含EFV方案抗HIV下直接抗HCV的疗效确切,未发现明显不良反应。展开更多
文摘研究分析化学发光法对人抗丙型肝炎病毒抗体(Human Hepatitis C virus antibodies,Anti-HCV)检测的临床应用价值。方法:随机选取我院2021年1月至2022年12月的30例丙型肝炎患者,将其视为本研究观察对象,对其采取时间分辨荧光免疫法、化学发光法对其Anti-HCV进行检查,研究分析其临床应用价值。结果:化学发光法临床Anti-HCV检出率高于时间分辨荧光免疫法,且检测时间低于时间分辨荧光免疫法,具备统计学差异(P<0.05)。结论:在临床检测Anti-HCV中使用化学发光法取得的临床应用价值较高,与时间分辨荧光免疫法相比,化学发光法能够提高临床检测的准确率,缩短检测时间,能够为临床诊疗方案的制定给予良好的参考依据,值得推荐。
文摘The study included 200 thalassemia patients, 120 （60%） males and 80 （40%） females, at age 2-30 years the mean age 16 years and 100 persons from blood donors at age 20-50 years, the mean age 35 years, as control group. The authors used ELISA HCV 3.0 to detect anti-HCV in serum of thalassemia patients and blood donors. The results show 17% positive, 76% negative and 7% equivocal in serum ofthalassemia patients, but show 1% positive, 98% negative, 1% equivocal in serum of blood donors. The results show significant difference in P ≤ 0.05 between prevalence of anti-HCV antibodies among thalassemia patients and blood donors, the confirmatory tests by recombinant immunoblot assay version 3.0 （RIBA） show 17.5% positive, 79% negative and 3.5% equivocal in serum of thalassemia patients but show 2% positive, 98% negative in serum of blood donors. The thalassemia patients in the present study region had high seroprevalence of anti-HCV.
基金This work was supported by the National Natural Science Fund for Young Scientists(No.81302645)Beijing National Natural Science Fund(No.7121009).
文摘Chronic hepatitis C virus(HCV)infection has become a major public health burden worldwide.Twenty-two sophocarpinic acid or matrine derivatives were synthesized and their anti-HCV activities were evaluated in vitro.The structure-activity analysis revealed that(i)sophocarpinic acids with a D-seco 3-ring structure scaffold were more favorable than matrines with a 4-ring scaffold;(ii)the introduction of an electron-withdrawing group on the phenyl ring in 12-N-benzenesulfonylΔβγsophocarpinic acids was beneficial for the antiviral activity against HCV.Among them,compounds 9h and 9j exhibited the most potent inhibitory activities on HCV replication with selectivity indies of 70.3 and 30.9,respectively.Therefore,both were selected as antiviral candidates for further investigation.
基金supported by the National Natural Science Foundation of China (Nos.81273439 and 81202414)Student Fund of Innovation Project of Peking Union Medical College (No.2013-1007-10)
文摘A series of novel N-phenylbenzamide and N-phenylacetophenone compounds were synthesized and evaluated for their antiviral activity against HCV and EV71(strain SZ-98).The biological results showed that three compounds(23,25 and 41) exhibited considerable anti-HCV activity(IC50? 0.57–7.12 μmol/L) and several compounds(23,28,29,30,31 and 42) displayed potent activity against EV71 with the IC50 values lower than 5.00 μmol/L.The potency of compound 23(IC50? 0.57 μmol/L) was superior to that of reported compounds IMB-1f(IC50? 1.90 μmol/L) and IMB-1g(IC50? 1.00 μmol/L) as anti-HCV agents,and compound29 possessed the highest anti-EV71 activity,comparable to the comparator drug pirodavir.The efficacy in vivo and antiviral mechanism of these compounds warrant further investigations.
文摘Two hundred and ninety-six samples of patient serum and 28 samples of donor serum were tested for anti-HCV with second generation domestic made testing kit,and for HCV RNA with PCR assay.The purpose of the study was
文摘目的评价人类免疫缺陷病毒(human immunodeficiency virus,HIV)和丙型肝炎病毒(hepatitis C virus,HCV)共感染患者基于含依非韦伦(Efavirenz,EFV)方案抗HIV下直接抗HCV治疗的疗效和安全性。方法选取2020年1月至2023年9月梧州市第三人民医院感染科收治的基于含EFV方案抗HIV下索磷布韦维帕他韦直接抗HCV治疗的HIV和HCV共感染患者21例,疗程12周,停药随访12周,分析患者基线特征,比较治疗前后白细胞、血红蛋白、血小板、肝肾功能,评估患者基于抗HIV情况下直接抗HCV治疗的疗效以及停药12周病毒持续应答率和安全性。结果21例HIV和HCV共感染的患者基于含EFV方案抗HIV下,接受索磷布韦维帕他韦抗HCV治疗12周,停药随访12周,HCV病毒应答率均达到100%。与治疗前比较,患者血清丙氨酸转氨酶和天冬氨酸转氨酶水平降低(P<0.01),白细胞、血小板、血肌酐差异无统计学意义(P>0.05)。结论HIV和HCV共感染患者基于含EFV方案抗HIV下直接抗HCV的疗效确切,未发现明显不良反应。
